(+)-UH 232 maleate
D2 antagonist (Ki = 72.7 nM in a ligand binding assay; apparent KB = 14.5 nM in a cAMP accumulation assay); displays preferential activity at central dopamine autoreceptors. Stimulates a marked acceleration of dopamine synthesis and turnover. Produces locomotor stimulation. Exhibits little or no activity at central noradrenalin and 5-HT receptors. Also D3 partial agonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 50 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 391.51. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.55 mL||12.77 mL||25.54 mL|
|5 mM||0.51 mL||2.55 mL||5.11 mL|
|10 mM||0.26 mL||1.28 mL||2.55 mL|
|50 mM||0.05 mL||0.26 mL||0.51 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Griffon et al (1995) The preferential dopamine D3 receptor ligand, (+)-UH 232, is a partial agonist. Eur.J.Pharmacol. 282 R3 PMID: 7498261
Hall and Strange (1997) Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br. J. Pharmacol. 121 731 PMID: 9208141
Johansson et al (1985) Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. J.Med.Chem. 28 1049 PMID: 3927002
Svensson et al (1986) (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch.Pharmacol. 334 234 PMID: 2880302
If you know of a relevant reference for (+)-UH 232 maleate, please let us know.
View Related Products by Product Action
Keywords: (+)-UH 232 maleate, supplier, D2-like, autoreceptor, antagonists, D3, partial, agonists, Dopamine, Non-Selective, Receptors, dopaminergic, (+)-UH232, maleate, D2, Receptors, Tocris Bioscience
Citations for (+)-UH 232 maleate
Citations are publications that use Tocris products.
Currently there are no citations for (+)-UH 232 maleate. Do you know of a great paper that uses (+)-UH 232 maleate from Tocris? If so please let us know.
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.